The short answer: tirzepatide produced larger average weight reduction than semaglutide in the trials, including in a direct head-to-head comparison. That does not make it the right medication for everyone. Tolerability, medical history, cost and availability all shift the decision, and for a substantial number of people semaglutide is the better fit.
Neither is a medication you should choose for yourself from an article. Candidacy, dose and continuation are clinical decisions made from your full medical picture. What this page can do is tell you what the difference actually is, so the consultation starts further along.
What they have in common
Both are weekly self-administered injections. Both work substantially by slowing gastric emptying and acting on appetite regulation in the brain, which is why people describe the effect as food simply occupying less of their attention rather than as forced restriction.
Both are titrated slowly, starting low and stepping up over months, because side effects track closely with how fast the dose rises. Both carry the same broad side-effect profile, dominated by gastrointestinal effects early on. And both work considerably better alongside sustained changes to nutrition and movement than they do alone.
Both also share the same class contraindications. Neither is prescribed in pregnancy, planned pregnancy or breastfeeding, with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, in active pancreatitis or severe gastrointestinal conditions, or in type 1 diabetes. Our medical weight loss page carries the full screening picture.
How each one works
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut releases after eating that signals fullness, slows stomach emptying and moderates blood sugar. Semaglutide binds that one receptor and holds the signal on for roughly a week per dose.
Tirzepatide is a dual agonist. It acts on the same GLP-1 receptor and also on the GIP receptor, a second gut hormone pathway involved in insulin response and fat metabolism. Engaging both appears to produce a larger metabolic effect than engaging GLP-1 alone, which is the mechanistic explanation for the difference in the trial results.
That is the entire structural difference between them. Everything else — weekly dosing, slow titration, the shape of the side-effect curve — is broadly shared.
What the trials found
Both medications were studied in large randomised trials alongside lifestyle intervention, and the figures below are averages across thousands of participants over roughly a year and a half. Individual results vary widely around those averages in both directions.
- Semaglutide at the weight-management dose produced mean weight reduction of roughly 15% in the STEP trial program.
- Tirzepatide produced mean reductions of roughly 15% to 21% across its dose range in the SURMOUNT-1 trial, with the higher figure at the highest dose.
- Head to head, the SURMOUNT-5 trial compared the two directly and found greater average weight reduction with tirzepatide.
Read those numbers carefully. They are averages achieved with structured lifestyle support, at maximum tolerated doses, over long periods, in people who met trial criteria. They are not a forecast for any individual, and a meaningful proportion of participants in both groups did considerably better or worse than the mean. Anyone quoting you a percentage as a prediction is misrepresenting how these trials work.
Side by side
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Receptors targeted | One | Two |
| Administration | Weekly injection | Weekly injection |
| Titration | Stepped up gradually over months | Stepped up gradually over months |
| Trial average weight reduction | ~15% (STEP program) | ~15–21% by dose (SURMOUNT-1) |
| Head-to-head result | Lower average reduction | Greater average reduction (SURMOUNT-5) |
| Common early side effects | Nausea, reduced appetite, slowed digestion, constipation or diarrhea | Same profile |
| Class contraindications | Pregnancy · MTC or MEN 2 history · pancreatitis · type 1 diabetes | Same |
| Cost | Medication pricing moves with market availability, so we review it at consultation rather than publish a figure that ages badly. Indicative starting figures are on the medical weight loss page. | |
Why the stronger option is not automatically the right one
If tirzepatide produces larger average reductions, the obvious question is why anyone would be prescribed semaglutide. Several real reasons:
- Tolerability. A medication you cannot stay on is not more effective for you, whatever the trial averages say. Some people tolerate one considerably better than the other, and there is no way to know in advance.
- You may not need the ceiling. If your goal is a moderate reduction, reaching it comfortably on a lower-intensity option beats pushing a stronger one.
- Cost. There is usually a meaningful price difference, and a plan you can sustain for a year beats a better plan you stop after three months.
- Availability. Supply of these medications has been volatile. What is obtainable changes, and it legitimately shapes what gets prescribed.
- Your medical history. Other conditions, other medications and prior response all bear on the choice in ways an article cannot anticipate.
The best medication is the one you can tolerate, afford, and stay on long enough for it to matter.
Side effects, without burying them
Most people experience some gastrointestinal effects in the first weeks: nausea, reduced appetite, slowed stomach emptying, and constipation or diarrhea. These typically settle as the body adjusts, and dose adjustment is the usual lever when they do not.
Less common but more serious effects exist for both medications, and they are discussed in full at consultation and monitored throughout the program rather than mentioned once and forgotten. Rapid dose escalation is the most avoidable cause of a bad experience, which is why the titration schedule is slow on purpose.
One more thing worth planning for: muscle loss. Rapid weight reduction takes muscle as well as fat unless protein intake and resistance training are deliberately maintained. Body composition testing is how you find out whether what you are losing is what you meant to lose, and it is a more useful measure than the scale.
What happens when you stop
Most people regain some weight after stopping either medication, particularly where lifestyle anchors are not established. This is not a failure of willpower and it is not a criticism of the drugs; it reflects what the medication is doing while you take it.
It does mean the honest framing is long-term rather than a course you complete. That conversation — when to titrate, when to hold, when stopping makes sense — belongs in your monthly check-ins from the beginning, not at the end.
Questions worth asking any provider
Whether you come to us or not, these are worth asking, and they are the same questions in our guide to choosing a practice applied to this specific program:
- Will I have in-person clinical follow-up, or is this prescription-only?
- What labs do you run before starting, and at what intervals afterwards?
- How is my dose decided, and how quickly does it escalate?
- Is the medication branded or compounded, and where is it sourced?
- What is the plan for maintaining muscle while I lose weight?
- What happens if I need to stop?
Our own program runs on a weekly injection with monthly clinical check-ins, labs at appropriate intervals, and time set aside for nutrition and how you are actually feeling rather than just a refill. Which medication we recommend is decided from your history, not from a preference. [PLACEHOLDER: confirm whether CAW dispenses branded, compounded, or both — this is the question patients ask most and the page should answer it plainly.]
